NEW YORK (GenomeWeb) – Having raised $200 million in financing over the last year, Somalogic is ending its fee-for-service business to focus on developing its SomaScan platform as a clinical tool.
The company is establishing collaborations with pharmaceutical companies, health systems, and other organizations that will allow it to collect and test the patient data it hopes to ultimately package for clinical use, said Stephen Williams, Somalogic's chief medical officer.